APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) (NCT03615235)
🩺 Plain-English Summary (8th-Grade Level)
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (2 items).
Location: University of Alabama at Birmingham — Birmingham, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria for Living Donors:
- Participants who are unable or unwilling to provide informed consent. Enrollment and bio sample collection from deceased donors at OPOs ended on May 31, 2023 and recruiting kidney transplant recipients ended on June 15, 2023. Phase II started on 9/1/2023 and only Living Donors will be recruited for an additional 2 years.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (18 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- University of California San Francisco — San Francisco, California
- University of Miami / Miami Transplant Institute — Miami, Florida
- Emory University School of Medicine — Atlanta, Georgia
- University of Maryland School of Medicine — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- Joslin Diabetes Center / Harvard University — Boston, Massachusetts
- University of Michigan Medicine — Ann Arbor, Michigan
- Saint Louis University Center for Transplantation — St Louis, Missouri
- Ichan School of Medicine at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Weill Cornell Medicine — New York, New York
- Duke University — Durham, North Carolina
- Wake Forest School of Medicine — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Wisconsin - Madison — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Diseases
- Access to Kidney Transplantation in Minority Populations — Albuquerque, New Mexico
- NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities — Denver, Colorado
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) — New York, New York
- Promoting Increases in Living Donation Via Tele-navigation (PILOT) — Birmingham, Alabama
- PRevEnting FracturEs in REnal Disease - 1 — Kingston, Ontario
Explore by condition: All Kidney Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.